Volume

(redirected from end-diastolic volume)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Volume

This is the daily number of shares of a security that change hands between a buyer and a seller. Also known as volume traded. Also see Up volume and Down volume.

volume

The amount of trading sustained in a security or in the entire market during a given period. Especially heavy volume may indicate that important news has just been announced or is expected. See also average daily volume.

Volume.

Volume is the number of shares traded in a company's stock or in an entire market over a specified period, typically a day.

Unusual market activity, either higher or lower than average, is typically the result of some external event. But unusual activity in an individual stock reflects new information about that stock or the stock's sector.

References in periodicals archive ?
36)] and mass/end-diastolic volume ratio, as well as with lower end-diastolic volume [-1.
Global end-diastolic volume and cardiac function index may be useful additional measures of left ventricular preload and myocardial contractility in patients with severe left ventricular dysfunction.
5 End-diastolic volume, LV, ml 120 120 End-systolic volume, LV, ml 40-50 40 Stroke volume, ml 80 100 Ejection fraction, % 67 67 Cardiac output, l/min, rest 4-7 5.
LV end-systolic and end-diastolic volumes, mitral early inflow velocity (E) were also recorded and E/ Vp ratio was calculated.
EF- ejection fraction, LV- left ventricle, LVEDVI- left ventricular end-diastolic volume index, LVESVI- left ventricular end-systolic volume index, group 1- controls, group 2- patients with nonrestrictive filling pattern, group 3- patients with restrictive filling pattern.
Left ventricular (LV) end-diastolic volumes and end-systolic volumes were measured from an apical two- and four-chamber view using the modified Simpson's method.
However, non-significant group differences in certain pre-specified secondary endpoints, including changes in left ventricular end-systolic and end-diastolic volumes (LVESV and LVEDV), suggest a potential beneficial effect from CAP-1002 on remodeling, one of the major culprits in the development of chronic heart failure.
The FDA agreed to Fast Track designation because the drug had demonstrated a reduction in mortality, hospitalisation and improvement of quality of life in patients suffering from chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) between 200 and 370ml.
0128), respectively, and were associated with statistically significant reductions in left ventricular end-systolic and end-diastolic volumes.
Also, the absolute decreases in LV end-systolic volumes and end-diastolic volumes at 18 months in the WJMSC group were significantly greater than those in the placebo group.